Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative

Betge, Johannes ; Barat, Ana ; Murphy, Verena ; Hielscher, Thomas ; Van Grieken, Nicole C. ; Belle, Sebastian ; Zhan, Tianzuo ; Härtel, Nicolai ; Kripp, Melanie ; Bacon, Orna ; Cordes, Martijn ; Kay, Elaine W. ; Verheul, Henk M.W. ; Neerincx, Maarten ; Hennessy, Bryan ; Hofheinz, Ralf D. ; Gaiser, Timo ; Ylstra, Bauke ; Prehn, Jochen H.M. ; Lambrechts, Diether ; Byrne, Annette T. ; Ebert, Matthias P. ; Schulte, Nadine

In: Digestion, 94 (2016), Nr. 3. pp. 129-137. ISSN 0012-2823 (Druck-Ausg.), 1421-9867 (Online-Ausg.)

[img] PDF, English - main document
Download (139kB) | Terms of use

Official URL:
Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.


Background/Aims: This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.

Methods: Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan–Meier method and uni- and multivariable Cox proportional hazards regression models.

Results: The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.

Conclusion: The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.

Item Type: Article
Journal or Publication Title: Digestion
Volume: 94
Number: 3
Publisher: Karger
Place of Publication: Basel ; Freiburg
Date Deposited: 04 Nov 2019 10:52
Date: 2016
ISSN: 0012-2823 (Druck-Ausg.), 1421-9867 (Online-Ausg.)
Page Range: pp. 129-137
Faculties / Institutes: Medizinische Fakultät Mannheim > Medizinische Klinik - Lehrstuhl für Innere Medizin II
Service facilities > German Cancer Research Center (DKFZ)
Subjects: 610 Medical sciences Medicine
Uncontrolled Keywords: Bevacizumab , colorectal cancer , combination chemotherapy , elderly patients , prognostic factor
Additional Information: Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich. This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative